Q3 2026 Fortis Healthcare Ltd Earnings Call Transcript
Key Points
- Fortis Healthcare Ltd (BOM:532843) reported a consolidated revenue growth of 17.5% year-on-year, reaching INR2,265 crore for Q3 FY26.
- The hospital business saw a revenue increase of 19.4% to INR1,938 crore, with an improvement in operating EBITDA margin from 20% to 21.7%.
- The diagnostics business reported a revenue growth of 7.3% to INR327 crore, with operating EBITDA margins improving significantly from 14.4% to 23.1%.
- The company successfully added approximately 750 operational beds during the year, including acquisitions and expansions, enhancing its capacity.
- Fortis Healthcare Ltd (BOM:532843) continues to focus on cluster-based inorganic growth, acquiring the 125-bedded People Tree Hospital in Bengaluru, with plans to expand to 300 beds.
- The consolidated profit after tax (PAT) declined to INR197 crore from INR250 crore in Q3 FY25, primarily due to a one-off expense related to new labor codes.
- The Gleneagles O&M agreement reported a negative revenue growth of 4% for the nine months, with challenges such as clinician attrition and management changes.
- The company's net debt increased to INR2,547 crore, with a net debt to EBITDA ratio of 1.24 times, partly due to recent acquisitions.
- Some facilities, like the Greater Noida and Adayu units, are dragging down overall occupancy rates, impacting the company's operational efficiency.
- The competitive landscape in regions like Hyderabad poses challenges for Fortis Healthcare Ltd (BOM:532843) in maintaining its market position.
Ladies and gentlemen, good day, and welcome to the Fortis Healthcare Limited Q3 FY26 earnings conference call. (Operator Instructions) Please note that this conference is being recorded. I would now like to hand the conference over to Mr. Anurag Kalra, the Head of Investor Relations for the opening remarks. Thank you, and over to you, sir.
Thank you, Alarick. A very good morning, good afternoon, ladies and gentlemen. Welcome to Fortis Healthcare's quarter three FY26 earnings call. The call is being led by our MD and CEO, Dr. Ashutosh Raghuvanshi. With him, we have our Chief Financial Officer, Mr. Vivek Goyal. From Agilus Diagnostics, Mr. Anand, the CEO, joins us. Along with him, we have Mr. Akshay Tiwari, the CFO. We will start with some opening comments by Dr. Raghuvanshi, post which Anand will take you through the highlights of the diagnostics business, and then we can open the floor for question and answers. Over to Dr. Raghuvanshi. Sir.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
